PIPELINE
Expanding the universe of new treatments for patients
Our pipeline of rSM medicines
We have taken a matrixed approach to building our pipeline of RNA-targeted small molecule (rSM) medicines by pursuing different rSM modalities across deeply researched, valuable drug targets, including: known targets implicated in important disease biology that have historically proved “undruggable” with today’s conventional medicines; and other genetically and pharmacologically validated targets in cancer, rare disease, and cardiovascular disease.
We are building a pipeline to maximize the number of rSM medicines for patients.
Arrakis has a pipeline of RNA-targeted drug programs that show promise for addressing a range of diseases, including cancer, cardiovascular conditions, neurodegeneration and rare diseases. In addition to wholly-owned programs for rSM medicines in our internal pipeline, we are establishing collaborations with large biopharmaceutical partners to expand the productivity of our platform.
Collaborations to expand value:
As an example of our partnership model, learn about our strategic collaborations with
Roche and Amgen.
